Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pain, Postoperative 1 Pain 1 Lymphoma, Non-Hodgkin 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Rituximab 155 Cyclophosphamide 120 fludarabine phosphate 71 Whole-Body Irradiation 55 Mycophenolic Acid 54 Etoposide 53 Peripheral Blood Stem Cell Transplantation 46 fludarabine 45 Melphalan 44 Granulocyte Colony-Stimulating Factor 43 Busulfan 43 Tacrolimus 39 Filgrastim 37 Vincristine 33 Cyclosporine 31 Bendamustine Hydrochloride 31 Prednisone 29 Doxorubicin 29 Antilymphocyte Serum 28 Methotrexate 27 Cytarabine 27 Lenalidomide 23 Carmustine 22 Bortezomib 22 plerixafor 20 Dexamethasone 19 Thiotepa 17 Stem Cell Transplantation 17 Radiotherapy 17 tositumomab I-131 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Lymphoma, Non-Hodgkin × Analgesics × Clear all

NCT00719472 2017-05-15

RATE

Genentech, Inc.

Phase 3 Completed

451 enrolled 11 charts

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡